Filana Therapeutics, Inc. (FLNA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
15/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseFLNA / S&P -29.59% / 15.20% |
LoseFLNA / S&P FLNA unavailable / 15.00% |
LoseFLNA / S&P FLNA unavailable / 50.40% |
| 2026-Q10/3 |
LoseFLNA / S&P -14.65% / -4.33% |
LoseFLNA / S&P FLNA unavailable / 11.30% |
LoseFLNA / S&P FLNA unavailable / 27.70% |
| 2025-Q41/3 |
LoseFLNA / S&P -31.96% / 2.65% |
LoseFLNA / S&P FLNA unavailable / 9.00% |
WinFLNA / S&P 28.77% / 13.40% |
| 2025-Q32/3 |
WinFLNA / S&P 60.77% / 8.12% |
LoseFLNA / S&P FLNA unavailable / 4.61% |
WinFLNA / S&P 59.42% / 13.45% |
| 2025-Q22/3 |
WinFLNA / S&P 20.67% / 10.94% |
LoseFLNA / S&P FLNA unavailable / 4.83% |
WinFLNA / S&P 81.56% / 10.63% |
| 2025-Q10/3 |
LoseFLNA / S&P -36.44% / -4.27% |
LoseFLNA / S&P FLNA unavailable / 4.98% |
LoseFLNA / S&P -30.41% / 10.57% |
| 2024-Q40/3 |
LoseFLNA / S&P -91.98% / 2.41% |
LoseFLNA / S&P FLNA unavailable / 5.25% |
LoseFLNA / S&P -37.07% / 6.15% |
| 2024-Q31/3 |
WinFLNA / S&P 138.30% / 5.89% |
LoseFLNA / S&P FLNA unavailable / 5.89% |
LoseFLNA / S&P FLNA unavailable / 6.11% |
| 2024-Q20/3 |
LoseFLNA / S&P -39.13% / 4.28% |
LoseFLNA / S&P FLNA unavailable / 5.38% |
LoseFLNA / S&P FLNA unavailable / 5.12% |
| 2024-Q10/3 |
LoseFLNA / S&P -9.86% / 10.56% |
LoseFLNA / S&P FLNA unavailable / 5.71% |
LoseFLNA / S&P FLNA unavailable / 5.59% |
| 2023-Q41/3 |
WinFLNA / S&P 35.28% / 11.69% |
LoseFLNA / S&P FLNA unavailable / 6.81% |
LoseFLNA / S&P FLNA unavailable / 7.78% |
| 2023-Q30/3 |
LoseFLNA / S&P -32.14% / -3.27% |
LoseFLNA / S&P FLNA unavailable / 7.52% |
LoseFLNA / S&P FLNA unavailable / -5.03% |
| 2023-Q20/3 |
LoseFLNA / S&P 1.66% / 8.74% |
LoseFLNA / S&P FLNA unavailable / 9.50% |
LoseFLNA / S&P FLNA unavailable / -8.57% |
| 2023-Q10/3 |
LoseFLNA / S&P -18.35% / 7.50% |
LoseFLNA / S&P FLNA unavailable / 10.77% |
LoseFLNA / S&P FLNA unavailable / -15.69% |
| 2022-Q40/3 |
LoseFLNA / S&P -29.36% / 7.56% |
LoseFLNA / S&P FLNA unavailable / 11.88% |
LoseFLNA / S&P FLNA unavailable / -17.99% |
| 2022-Q31/3 |
WinFLNA / S&P 48.72% / -4.88% |
LoseFLNA / S&P FLNA unavailable / 13.47% |
LoseFLNA / S&P FLNA unavailable / -1.41% |
| 2022-Q20/3 |
LoseFLNA / S&P -24.29% / -16.10% |
LoseFLNA / S&P FLNA unavailable / 13.71% |
LoseFLNA / S&P FLNA unavailable / 11.04% |
| 2022-Q10/3 |
LoseFLNA / S&P -15.01% / -4.60% |
LoseFLNA / S&P FLNA unavailable / 15.97% |
LoseFLNA / S&P FLNA unavailable / 42.23% |
| 2021-Q40/3 |
LoseFLNA / S&P -29.61% / 11.03% |
LoseFLNA / S&P FLNA unavailable / 15.00% |
LoseFLNA / S&P FLNA unavailable / 96.40% |
| 2021-Q30/3 |
LoseFLNA / S&P -27.34% / 0.58% |
LoseFLNA / S&P FLNA unavailable / 10.77% |
LoseFLNA / S&P FLNA unavailable / 69.42% |
| 2021-Q21/3 |
WinFLNA / S&P 90.08% / 8.55% |
LoseFLNA / S&P FLNA unavailable / 6.58% |
LoseFLNA / S&P FLNA unavailable / 51.81% |
| 2021-Q11/3 |
WinFLNA / S&P 559.09% / 6.17% |
LoseFLNA / S&P FLNA unavailable / -1.06% |
LoseFLNA / S&P FLNA unavailable / 7.39% |
| 2020-Q40/3 |
LoseFLNA / S&P -40.75% / 12.15% |
LoseFLNA / S&P FLNA unavailable / -3.72% |
LoseFLNA / S&P FLNA unavailable / -33.42% |
| 2020-Q31/3 |
WinFLNA / S&P 273.70% / 8.93% |
LoseFLNA / S&P FLNA unavailable / -2.04% |
LoseFLNA / S&P FLNA unavailable / -27.10% |
| 2020-Q20/3 |
LoseFLNA / S&P -25.06% / 20.54% |
LoseFLNA / S&P FLNA unavailable / -0.46% |
LoseFLNA / S&P FLNA unavailable / -27.11% |
| 2020-Q10/3 |
LoseFLNA / S&P -20.96% / -19.60% |
LoseFLNA / S&P FLNA unavailable / 3.47% |
LoseFLNA / S&P FLNA unavailable / -14.75% |
| 2019-Q41/3 |
WinFLNA / S&P 333.33% / 9.07% |
LoseFLNA / S&P FLNA unavailable / 5.36% |
LoseFLNA / S&P FLNA unavailable / 2.99% |
| 2019-Q30/3 |
LoseFLNA / S&P -0.83% / 1.70% |
LoseFLNA / S&P FLNA unavailable / 5.02% |
LoseFLNA / S&P FLNA unavailable / 0.21% |
| 2019-Q20/3 |
LoseFLNA / S&P -6.20% / 4.30% |
LoseFLNA / S&P FLNA unavailable / 6.64% |
LoseFLNA / S&P FLNA unavailable / 8.65% |
| 2019-Q11/3 |
WinFLNA / S&P 51.76% / 13.65% |
LoseFLNA / S&P FLNA unavailable / 8.12% |
LoseFLNA / S&P FLNA unavailable / 14.29% |
| 2018-Q40/3 |
LoseFLNA / S&P -15.84% / -13.52% |
LoseFLNA / S&P FLNA unavailable / 9.05% |
LoseFLNA / S&P FLNA unavailable / 18.23% |
| 2018-Q30/3 |
LoseFLNA / S&P -50.97% / 7.71% |
LoseFLNA / S&P FLNA unavailable / 10.21% |
LoseFLNA / S&P FLNA unavailable / 19.06% |
| 2018-Q20/3 |
LoseFLNA / S&P -70.94% / 3.43% |
LoseFLNA / S&P FLNA unavailable / 9.03% |
LoseFLNA / S&P FLNA unavailable / 14.46% |
| 2018-Q11/3 |
WinFLNA / S&P 77.25% / -0.76% |
LoseFLNA / S&P FLNA unavailable / 7.68% |
LoseFLNA / S&P FLNA unavailable / 12.46% |
| 2017-Q40/3 |
LoseFLNA / S&P -1.72% / 6.64% |
LoseFLNA / S&P FLNA unavailable / 7.03% |
LoseFLNA / S&P FLNA unavailable / 13.82% |
| 2017-Q30/3 |
LoseFLNA / S&P -1.93% / 4.48% |
LoseFLNA / S&P FLNA unavailable / 5.68% |
LoseFLNA / S&P FLNA unavailable / 17.57% |
| 2017-Q20/3 |
LoseFLNA / S&P -33.39% / 3.09% |
LoseFLNA / S&P FLNA unavailable / 4.83% |
LoseFLNA / S&P FLNA unavailable / 17.74% |
| 2017-Q11/3 |
WinFLNA / S&P 56.14% / 6.07% |
LoseFLNA / S&P FLNA unavailable / 3.67% |
LoseFLNA / S&P FLNA unavailable / 13.32% |
| 2016-Q40/3 |
LoseFLNA / S&P -43.00% / 3.82% |
LoseFLNA / S&P FLNA unavailable / 2.09% |
LoseFLNA / S&P FLNA unavailable / 7.05% |
| 2016-Q30/3 |
LoseFLNA / S&P -54.34% / 3.85% |
LoseFLNA / S&P FLNA unavailable / 0.20% |
LoseFLNA / S&P FLNA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | FLNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -59.65% | 20.78% |
| Annualized return | -59.65% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | FLNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.23% | 83.14% |
| Annualized return | -55.37% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | FLNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.33% | 319.30% |
| Annualized return | -24.96% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |